Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors

NCT07108114 is registered in ClinicalTrials.gov with Solve Therapeutics as lead sponsor.

NCT NCT07108114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07108114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors
Lead sponsor
Solve Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
August 25, 2025
Completion date
August 31, 2027
Enrollment
70 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors